RxDoctor Payments Data

Michael Landor, MD

Allergy/ Immunology · Flushing, NYNPI 1245293687

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.1% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AstraZeneca at 26.8% of the total.

$2,223in general payments, 2019–2025

Across 101 payments — averaging $22.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$595
  • GSK$491
  • Sanofi$235
  • Regeneron Healthcare Solutions, Inc.$228
  • Viiv Healthcare Company$186
  • Bio Products Laboratory USA, Inc.$147
  • plus $341 from 8 others

What the payments were for

  • Food & beverage$2,13796%
  • Education$864%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy/ immunology providers in New Yorkto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$40,782
Medicare patients
36
Services billed
2,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FasenraBenralizumab11$64,148
Dupixent SyringeDupilumab17$59,724
Zileuton ErZileuton20$49,031
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$38,501
AirsupraAlbuterol Sulfate/Budesonide22$9,796
Breo ElliptaFluticasone/Vilanterol11$5,782
Epinephrine25$5,393
Azelastine Hcl63$1,728
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,489
Albuterol Sulfate HfaAlbuterol Sulfate31$1,017
Fluticasone Propionate61$669
Montelukast Sodium27$343
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav16$123
Fluconazole17$70
Prednisone14$22

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFasenra, Airsupra$595$73,94433 claims
GSKTrelegy Ellipta, Breo Ellipta$491$44,28369 claims
Hikma Pharmaceuticals USAEpinephrine$21$5,39325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in New Yorkon file to place this against a meaningful peer group, so we don't.

Other allergy/ immunology in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →